MYLAN 2045 MYLAN 2045 (Tacrolimus 0.5 mg)
Pill imprint MYLAN 2045 MYLAN 2045 has been identified as Tacrolimus 0.5 mg.
Tacrolimus is used in the treatment of organ transplant, rejection reversal; organ transplant, rejection prophylaxis; graft-versus-host disease; crohn's disease and belongs to the drug class calcineurin inhibitors. Risk cannot be ruled out during pregnancy. Tacrolimus 0.5 mg is not a controlled substance under the Controlled Substance Act (CSA).
- MYLAN 2045 MYLAN 2045
- 0.5 mg
- Orange / Gray
- Prescription only
- Drug Class:
- Calcineurin inhibitors
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- lactose anhydrous
sodium lauryl sulfate
ferric oxide yellow
D&C Red No. 28
D&C Yellow No. 10
FD&C Red No. 40
FD&C Blue No. 1
FD&C Blue No. 2
|NDC Code||Manufacturer / Repackager|
|51079-0817||UDL Laboratories Inc|
Note: Inactive ingredients may vary.
More about tacrolimus
- Tacrolimus capsules
- Tacrolimus extended-release capsules
- Tacrolimus oral and injection
- Tacrolimus Intravenous (Advanced Reading)
- Tacrolimus Oral, Intravenous (Advanced Reading)
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.